High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
复制标题
DOI：
10.1200/jco.1997.15.11.3363
复制
发表时间：
1997-11-01
影响因子：
45.3
通讯作者：
Cheever, MA
中科院分区：
文献类型：
--
作者：
Disis, ML;Pupa, SM;Cheever, MA
目的：评价乳腺癌患者HER-2/neu特异性抗体免疫，确定乳腺癌患者血清中HER-2/neu抗体的发生率，并探讨特异性免疫的存在与原发肿瘤中HER-2/neu蛋白过表达的关系。方法：对107例初诊乳腺癌患者HER-2/neu蛋白抗体反应进行分析。采用捕获酶联免疫吸附试验（ELISA）分析血清中HER-SI新特异性抗体的存在，并采用Western blot验证。200名志愿献血者的血清作为对照人群。结果：HER-2/neu抗体的存在与乳腺癌的存在相关。107例乳腺癌患者中有12例（11%）检测到HER-2/neu抗体滴度大于或等于1:100，而200例（O%）正常对照中没有检测到HER-2/neu抗体滴度
Purpose: To evaluate HER-2/neu-specific antibody immunity patients with breast cancer, to determine the rate of occurrence of serum antibodies to HER-2/neu in patients with breast cancer, and to relate the presence of specific immunity to overexpression of HER-2/neu protein in primary tumor.Methods: The antibody response to HER-2/neu protein was analyzed in 107 newly diagnosed breast cancer patients. Sera was analyzed for the presence of HER-SI neo-specific antibodies with a capture enzyme-linked immunosorbent assay (ELISA) and verified by Western blot. Sera from 200 volunteer blood donors was used as a control population.Results: The presence of antibodies to HER-2/neu correlated with the presence of breast cancer. HER-2/neu antibodies at titers of greater than or equal to 1:100 were detected in 12 of 107 (11%) breast cancer patients versus none of 200 (O%) normal controls (P